<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798991</url>
  </required_header>
  <id_info>
    <org_study_id>205181</org_study_id>
    <nct_id>NCT02798991</nct_id>
  </id_info>
  <brief_title>A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects</brief_title>
  <official_title>A Phase I, 14 Day, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Repeat Dose, Ascending Cohort Study to Evaluate the Safety, Tolerability Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to assess the safety, tolerability, pharmacokinetics (PK),
      gastrointestinal (GI) transit time and pharmacodynamic (PD) biomarkers of repeat oral doses
      of GSK3179106 administered for 14 days in normal healthy subjects. It is a randomized,
      double-blind, placebo-controlled, ascending cohort study. A total of 48 subjects will be
      randomized (8 subjects/cohort) with 3:1 allocation to GSK3179106 or matching placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse event (AE)</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>10 mg of GSK3179106 QD-Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible six subjects will receive 10 mg oral dose once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg of GSK3179106 QD-Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible six subjects will receive 50 mg oral dose once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg of GSK3179106 QD-Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible six subjects will receive 200 mg oral dose once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg of GSK3179106 QD-Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible six subjects will receive 400 mg oral dose once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg of GSK3179106 BID-Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible six subjects will receive 25 mg oral dose twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg of GSK3179106 BID-Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible six subjects will receive 200 mg oral dose twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo QD-Cohort 1, 2, 3, 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible two subjects, per cohort, will receive oral dose of matched placebo once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo BID-Cohort 5, 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible two subjects, per cohort, will receive oral dose of matched placebo twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3179106</intervention_name>
    <description>It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally</description>
    <arm_group_label>400 mg of GSK3179106 QD-Cohort 4</arm_group_label>
    <arm_group_label>25 mg of GSK3179106 BID-Cohort 5</arm_group_label>
    <arm_group_label>10 mg of GSK3179106 QD-Cohort 1</arm_group_label>
    <arm_group_label>200 mg of GSK3179106 QD-Cohort 3</arm_group_label>
    <arm_group_label>50 mg of GSK3179106 QD-Cohort 2</arm_group_label>
    <arm_group_label>200 mg of GSK3179106 BID-Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebo</intervention_name>
    <description>It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally</description>
    <arm_group_label>Matching placebo BID-Cohort 5, 6</arm_group_label>
    <arm_group_label>Matching placebo QD-Cohort 1, 2, 3, 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 55 years of age inclusive, at the time of signing the informed consent.

          -  Healthy as determined by the investigator based on a medical evaluation including
             medical history, physical examination, laboratory tests and cardiac monitoring.
             History of regular bowel habits

          -  Male or Female of non-childbearing potential.

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions

        Exclusion Criteria:

          -  ALT and bilirubin &gt;1.5xupper limit of normal (ULN) (isolated bilirubin &gt;1. ULN is
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).

          -  Estimated Glomerular Filtration Rate &lt;60 milliliter per minute per 1.73 square meter
             (mL/min/1.73m^2)

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones)

          -  History of Gastroesophageal reflux disease (GERD), dyspepsia, GI bleeding, GI surgery
             that could affect motility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>REarranged during Transfection Growth Factor Receptor Tyrosine Kinase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

